BioCentury
ARTICLE | Clinical News

Xiidra lifitegrast regulatory update

July 18, 2016 7:00 AM UTC

FDA approved an NDA from Shire for Xiidra lifitegrast to treat signs and symptoms of dry eye disease in adults. Shire plans to launch the product this quarter. Xiidra is an eye drop formulation of a small molecule integrin beta(2) (LFA-1; MAC-1; CD18) antagonist. ...